Literature DB >> 7513492

Cholangiography of icteric type hepatoma.

C S Wu1, S S Wu, P C Chen, C T Chiu, S M Lin, Y Y Jan, C F Hung.   

Abstract

OBJECTIVES: Icteric type hepatoma caused by floating tumor debris in the major bile duct was rare. Such cases were often incorrectly identified as biliary carcinoma or choledocholithiasis until pathological proof. The goal of this study was to analyze the cholangiograms of icteric type hepatomas, and to identify the characteristic cholangiographic features of this rare disease.
METHODS: A retrospective analysis of 20 cholangiographies of icteric type hepatomas during a 10-yr period was carried out.
RESULTS: There were 15 males and five females in this series. Seventeen (85%) patients were hepatitis B virus carriers, and liver cirrhosis was detected in 16 (80%) patients. Serum alpha-fetoprotein levels in 13 (65%) of the patients were over 400 ng/ml. The cholangiographic findings included: 1) intraductal filling defects resulting in partial or complete obstruction and ductal dilation in 14 cases (70%), 2) abrupt complete obstruction of the common hepatic duct with an irregular cut surface in three cases (15%), and 3) tumor encasement and stricture of the biliary system in three cases (15%). Management of these patients included hepatic resection, choledochotomies with T tube stenting, or PTCD. Most of them died within one-half year after diagnosis, but one patient in our series, who received hepatic resection, survived more than 70 months.
CONCLUSIONS: It is important to recognize this group of patients. Because with proper management, good palliation or cure is possible. The cholangiographic appearances, when taken alone, are not diagnostic of icteric type hepatomas. Once these cholangiograms are seen in patients with associated risks of developing a hepatoma, such as liver cirrhosis, chronic viral hepatitis, and elevated serum alpha-fetoprotein, however, an icteric type hepatoma should be suspected.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7513492

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  7 in total

1.  Refractory pancreatitis secondary to ruptured hepatocellular carcinoma into the common bile duct.

Authors:  T S Yeh; Y Y Jan; T C Chao; R N Chien; T C Chen; M F Chen
Journal:  Dig Dis Sci       Date:  2001-05       Impact factor: 3.199

2.  An icteric type hepatocellular carcinoma with no detectable tumor in the liver: report of a case.

Authors:  Tomoki Makino; Shoji Nakamori; Masaki Kashiwazaki; Norikazu Masuda; Masakazu Ikenaga; Motohiro Hirao; Kazumasa Fujitani; Hideyuki Mishima; Toshiro Sawamura; Masashi Takeda; Masayuki Mano; Toshimasa Tsujinaka
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

3.  Refractory pancreatitis secondary to ruptured hepatocellular carcinoma into the common bile duct.

Authors:  T S Yeh; Y Y Jan; T C Chao; R N Chien; T C Chen; M F Chen
Journal:  Dig Dis Sci       Date:  1998-01       Impact factor: 3.199

4.  Three cases of small hepatocellular carcinoma presenting as obstructive jaundice.

Authors:  N Ise; H Andoh; T Sato; O Yasui; T Kurokawa; H Kotanagi
Journal:  HPB (Oxford)       Date:  2004       Impact factor: 3.647

5.  Evaluation of endoscopic biliary stenting for obstructive jaundice caused by hepatocellular carcinoma.

Authors:  Gen Sugiyama; Yoshinobu Okabe; Yusuke Ishida; Fumihiko Saitou; Ryuichi Kawahara; Hiroto Ishikawa; Hiroyuki Horiuchi; Hisafumi Kinoshita; Osamu Tsuruta; Michio Sata
Journal:  World J Gastroenterol       Date:  2014-06-14       Impact factor: 5.742

Review 6.  Hepatocellular carcinoma with obstructive jaundice: diagnosis, treatment and prognosis.

Authors:  Lun-Xiu Qin; Zhao-You Tang
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

7.  A single institution report of 19 hepatocellular carcinoma patients with bile duct tumor thrombus.

Authors:  Anon Chotirosniramit; Akkaphod Liwattanakun; Worakitti Lapisatepun; Wasana Ko-Iam; Trichak Sandhu; Sunhawit Junrungsee
Journal:  J Hepatocell Carcinoma       Date:  2017-03-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.